Stayble Therapeutics AB

Investor

Stayble Therapeutics AB

Description

Injectable Back Pain Treatment

Stayble Therapeutics AB

Address

Lennart Torstenssonsgatan 6, SE-412 56 Göteborg
Gothenburg, Sweden

Contact

info@stayble.se / andreas.gerward@stayble.se

Description

Injectable Back Pain Treatment

Matchmaking

Connect with Stayble Therapeutics AB

This entity is yours?

Update information

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

TRL

Stayble Therapeutics AB last news

03/04/2024

Abstract on STA363's clinical effect on disc volume has been accepted for presentation at an important congress

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company's scientific abstract regarding the treatment concept for herniated discs has been accepted for a poster presentation at the International Society for the Study of the Lumbar Spine (ISSLS) annual meeting in Milan, Italy, on 27-31 May 2024. The poster presents the STA363 results on lumbar discs from the phase 2b study in degenerative disc disease (DDD) and explains why STA363 can have a treatment effect in patients with herniated discs. The result demonstrates a statistically significant reduction in both disc

05/03/2024

All patients included in Stayble Therapeutics' phase Ib study in disc hernia with STA363

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been included in the ongoing phase Ib clinical study with STA363 towards disc hernia. No significant side effects have so far been reported and currently, none of the included patients has discontinued their participation in the study. Results from the study are expected to be available in Q4 2024. The ongoing clinical trial, conducted in collaboration with the contract research company CromSource and at four clinics in Poland, is a double-blind, placebo-controlled trial aimed primarily at studying

20/02/2024

Stayble Therapeutics AB (publ) annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023 -Le 20 février 2024 à 08:00 | Zonebourse

Stayble Therapeutics AB a publié ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023. Pour le quatrième trimestre, la société a déclaré des revenus de 0,138...